Capacity of the manufacturing process of Flebogamma® DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent

Biologicals

Volumn 38, Issue 6, 2010, Pages 670-674

  Diez, José M ^a   Caballero, Santiago ^a   Belda, Francisco ^a   Otegui, Magdalena ^a   Gajardo, Rodrigo ^a   Jorquera, Juan I ^a  

^a Instituto Grifols   (Spain)

Author keywords

Flebogamma; Intravenous immunoglobulin; TSE clearance

Indexed keywords

FLEBOGAMMA DIF; IMMUNOGLOBULIN; MACROGOL; PRION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOASSAY; BRAIN HOMOGENATE; CLEARANCE; CONTROLLED STUDY; DILUTION; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG PURITY; FILTER; NANOFILTRATION; NONHUMAN; POLYETHYLENE GLYCOL PRECIPITATION; POROSITY; PRECIPITATION; PRION DISEASE; PRIORITY JOURNAL; VIRUS INFECTIVITY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CRICETINAE; FILTRATION; IMMUNOGLOBULINS, INTRAVENOUS; POLYETHYLENE GLYCOLS; PRION DISEASES; PRIONS;

BOS; BOVINAE; CRICETINAE;

EID: 78650248293     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.08.003     Document Type: Article

References (39)

1. Prusiner S.B. Prion Biology and Diseases 2003, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
2. Hewitt P.E., Llewelyn C.A., Mackenzie J., Will R.G. Creutzfeldt-Jacob disease and blood transfusion: results of the UK transfusion medicine epidemiological review study. Vox Sang 2006, 91:221-230.
3. Dorsey K., Zou S., Schonberger L.B., Sullivan M., Kessler D., Notari E., et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jacob disease in a US surveillance study. Transfusion 2009, 49:977-984.
4. Chamberland M.E., Alter H.J., Busch M.P., Nemo G., Ricketts M. Emerging infectious disease issues in blood safety. Emerg Infect Dis 2001, 7:552-553.
5. Evatt B., Austin H., Barnhart E., Schonberger L., Sharer L., Jones R., et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998, 38:817-820.
6. Office International Des Epizooties - World animal heath situation Number of cases of bovine spongiform encephalopathy (BSE) reported in the United Kingdom [accessed 03.11.09]. http://www.oie.int/eng/info/en_esbru.htm.
7. Smith P.G., Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003, 66:185-198.
8. Brown P., Will R.G., Bradley R., Asher M.D., Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob Disease: background, evolution and current concern. Emerg Infect Dis 2001, 7:6-16.
9. The National Creutzfeldt-Jacob Disease Surveillance Unit (NCJDSU) [accessed 03.11.09]. http://www.cjd.ed.ac.uk/figures.htm.
10. The National Creutzfeldt-Jacob Disease Surveillance Unit (NCJDSU) [accessed 03.11.09]. http://www.cjd.ed.ac.uk/vcjdworld.htm.
11. Llewelyn C.A., Hewitt P.E., Knights R.S., Amar K., Cousens S., Mackenzie J., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363:417-421.
12. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004, 364:527-529.
13. Wroe S.J., Pal S., Siddique D., Hyare H., Macfarlane R., Joiner S., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006, 368:2061-2067.
14. Health Protection Agency 4th Case Variant CJD Infection Associated Blood Transfusion January 2007, vol. 19. HPA Press Statement, [accessed 28.04.09]. http://www.hpa.org.uk/webw/HPAweb%26HPAwebStandard/HPAweb_C/1195733711457%3Fp%3D1171991026241.
15. Darby S.C., Kan S.W., Spooner R.J., Giangrande P.L., Hill F.G., Hay C.R., et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007, 110:815-825.
16. World Federation of Hemophilia Signs of variant Creutzfeldt-Jakob disease in a patient with hemophilia: FVIII concentrates most likely cause. WFH Saf & Supply News 2009, 8. [accessed 23.04.09]. http://www.wfh.org/index.asp%3Flang%3DEN.
17. Peden A., McCardle L., Head M.W., Love S., Ward H.J., Cousens S.N., et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010, 16:296-304.
18. Lee C.A., Ironside J.W., Bell J.E., Giangrande P., Ludlam C., Esiri M.M., et al. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998, 80:909-911.
19. El-Shanawany T., Jolles S., Unsworth D.J., Williams P. A recipient of immunoglobulin from a donor who developed vCJD. Vox Sang 2009, 96:270.
20. Brown P. Creutfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007, 13(Suppl. 5):33-40.
21. Brown P., Cervenakova L., McShane L.M., Barber P., Rubenstein R., Drohan W.N. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999, 39:1169-1178.
22. Brown P., Rohwer R.G., Dunstan B.C., MacAuley C., Gajdusek D.C., Drohan W.N. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998, 38:810-816.
23. Brown P. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Vox Sang 2005, 89:63-70.
24. Stenland C.J., Lee D.C., Brown P., Petteway S.R., Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002, 42:1497-1500.
25. ®, a human factor VIII/VWF complex concentrate. Haemophilia 2009, 15:1249-1257.
26. Kärber G. Beitrag zur kollectiven Behandlung Pharmacologisher Reihenversuche. Archive Exp Pathologie Pharmakologie 1931, 162:480-483.
27. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
28. Gregori L., Gurgel P.V., Lathrop J.T., Eduwardson P., Lambert B.C., Carbonell R.G., et al. Reduction infectivity of endogenous transmissible spongiform encepahlopathies present in blood by adsorption to selective affinity resins. Lancet 2006, 368:2232-2236.
29. Lee D.C., Stenland C.J., Miller J.L., Cai K., Ford E.K., Gilligan K.J., et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001, 41:449-455.
30. Silveira J.R., Raymond G.J., Hughson A.G., Race R.E., Sim V.L., Hayes S.F., et al. The most infectious prion protein particles. Nature 2005, 437:257-261.
31. Diez JM, Caballero S, Domingo N, Belda FJ, Otegui M, Gajardo R et al. Efficacy of Flebogammadif® manufacturing process to eliminate an experimental TSE agent. XIIITh Meeting Eur Soc for Immunodeficiences 2008; Abstract P209.
32. Vey M., Baron H., Weimer T., Gröner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002, 30:187-196.
33. Lee D.C., Stenland C.J., Hartwell R.C., Ford E.K., Cai K., Miller J.L., et al. Monitoring plasma processing with a sensitive western blot assay for the detection of the prion protein. J Virol Methods 2000, 84:77-89.
34. Foster P.R., Welch A.G., McLean C., Griffin B.D., Hardy J.C., Bartley A., et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000, 78:86-95.
35. Foster P.R. Removal of TSE agents from blood products. Vox Sang 2004, 87(Suppl. 2):S7-10.
36. Reichl H.E., Foster P.R., Welch A.G., Li Q., MacGregor I.R., Somerville R.A., et al. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 2002, 83:137-145.
37. Lebing W., Remington K.M., Paul H.L. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003, 84:193-201.
38. Trejo S.R., Hotta J.A., Lebing W., Stenland C., Storms R.E., Lee D.C., et al. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003, 84:176-187.
39. Van Holten R.W., Autenrieth S.M. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003, 85:20-24.